Novo Nordisk has trimmed his income and earnings forecasts throughout the year for the first time since he launched his lush weight loss drug, since the unauthorized versions of his GLP-1 drugs eat in Laret. Itstés Itstés Itstés Itstés Itstés Itstés-itstes. Itstés
The Danish drug manufacturer, which also markets Ozempic for diabetes, now expects sales growth or from 13% to 21% in constant currencies this year, below its previous range or from 16% to 24%. It is also forecast that the operational profits will be lower, from 16% to 24%, compared to the previous estimate or from 19% to 27%.
“We have reduced our perspective of the whole year due to the penetration of LPG-1 of lower brand to planning, which is affected by the rapid expansion of composition in the United States,” said Lars Fruerd Jorgensen, CEO of Novo Nordisk.
The United States Food and Medicines Administration (FDA) had allowed pharmacies to aggravate their own versions of Semaglutide, the active ingredient in both Wogovy and Ozempic, to address supply shortage. But with the supply now stabilized, the FDA has ordered versions composed of thesis outside the market before May 22, the sacrifice Novo a potential leverage.
Novo shares increased 6.8% in Copenhagen after the news, despite the revised perspective, since the company said that the growth of the recipes for Wegovy is expected to recover once the prohibition is applied.
Although sales in sales increased 83% year -on -year to $ 2.65 billion, growth was below the expectations of analysts and below the previous quarter. Ozempic recorded an increase of 15%, slightly ahead of forecasts.
Novo estimates that composite pharmacies have captured almost a third of the US obesity medication market. Uu., Rent their domain in the rapidly growing LPG-1 sector.
“It has no precedents in our industry to have very large volumes of products that flow to patients who are not approved,” said Jorgens.
Anxiety for investors has also grown over intense competition, particularly from the American rival Eli Lilly, who has won traction with the tirzepatido, marked as Mounjaro for diabetes and Zepbound for Obesity. Lilly recently announced the positive test data for the weight loss pill, which increased on the future participation of Novo in the GLP-1 injectable market.
Other pharmaceutical giants, including Astrazeneca, are running to develop next -generation oral alternatives, which are cheaper to produce, easier to distribute and can sacrifice the patient’s results by preserving the weight of the duration of the mass.
To combat supply problems, Novo has made aggressive investments, including the acquisition of $ 11 billion of three Catalant factories, the manufacturer of contracts based in the United States, in an attempt to expand production.
Jorgesen also addressed growing groups on possible pharmaceutical tariffs of the administration of President Trump, stating that Novo is a net exporter of the United States, where he operates multiple production sites and employs about 10,000 people.
“We have a strong American footprint,” he said, emphasizing that most GLP-1 products of the company are manufactured in the United States and send worldwide.
While Novo’s LPG-1 franchise remains the market leader, the era of uninterrupted growth can be approximately as price pressure, regulatory changes and a fierce competition interrupt the sector.
Investors will now analyze closely how Novo sails for their US supply dynamics, defends their market share against new participants and transitions to the next phase of the product innovation pipe, including possible oral therapies.
